Edgar Filing: CATALYST PHARMACEUTICALS, INC. - Form 3

CATALYST PHARMACEUTICALS, INC.

Form 3

September 16, 2015

FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL

OMB Number:

3235-0104

Expires:

response...

January 31, 2005

0.5

Estimated average burden hours per

SECURITIESFiled pursuant to Section 16(a) of the Securities Exchange Act of 1934,

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF

Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting 2. Date of Event Requiring 3. Issuer Name and Ticker or Trading Symbol Person * Statement CATALYST PHARMACEUTICALS, INC. [CPRX] A Merrigan Paul J (Month/Day/Year) 09/08/2015 (Last) (First) (Middle) 4. Relationship of Reporting 5. If Amendment, Date Original Person(s) to Issuer Filed(Month/Day/Year) 355 ALHAMBRA (Check all applicable) CIRCLE, Â SUITE 1250 (Street) 6. Individual or Joint/Group 10% Owner Director _X__ Officer Other Filing(Check Applicable Line) (give title below) (specify below) _X_ Form filed by One Reporting Chief Commercial Officer Person **FORT** Form filed by More than One LAUDERDALE, Â FLÂ 33134 Reporting Person (City) (State) (Zip) Table I - Non-Derivative Securities Beneficially Owned 4. Nature of Indirect Beneficial 1. Title of Security 2. Amount of Securities Beneficially Owned Ownership Ownership (Instr. 4) (Instr. 4) Form: (Instr. 5) Direct (D) or Indirect (I) (Instr. 5)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security 2. Date (Instr. 4) Expirati (Month/Day		sable and te	3. Title and Amount of Securities Underlying Derivative Security		4. Conversion or Exercise	5. 6. Nature of Ownership Beneficial Form of Ownership	
	Date Exercisable	Expiration Date	(Instr. 4) Title	Amount or Number of Shares	Price of Derivative Security	Derivative Security: Direct (D) or Indirect (I)	(Instr. 5)

Edgar Filing: CATALYST PHARMACEUTICALS, INC. - Form 3

						(Instr. 5)	
Options to purchase common stock	09/08/2016	09/08/2022	Common Stock	50,000	\$ 3.89	D	Â
Options to purchase common stock	(1)	09/08/2022	Common Stock	(1)	\$ 3.89	D	Â
Options to purchase	09/08/2018	09/08/2022	Common	4,159	\$ 3.89	D	Â

Reporting Owners

Reporting Owner Name / Address	Relationships					
FG	Director	10% Owner	Officer	Other		
Merrigan Paul J 355 ALHAMBRA CIRCLE SUITE 1250 FORT LAUDERDALE, FL 33134	Â	Â	Chief Commercial Officer	Â		

Signatures

/s/ Paul J.
Merrigan

**Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) 4,167 shares will vest on a monthly basis on the 8th of each month commencing on October 8, 2016 through and until August 8, 2018. Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 2